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Abstract  
Human natural killer (NK) cells play an important role in antiviral immunity. 
However, studying their activation kinetics during infection is highly problematic. A 
clinical trial of a therapeutic virus provided an opportunity to study human NK cell 
activation in vivo in a controlled manner.  Ten colorectal cancer patients with liver 
metastases received between one and five doses of oncolytic reovirus prior to surgical 
resection of their tumour. NK cell surface expression of the interferon-inducible 
molecules CD69 and tetherin peaked twenty-four to forty-eight hours post-infection, 
coincident with a peak of interferon-induced gene expression. The interferon response 
and NK cell activation were transient, declining by ninety-six hours post-infection. 
Furthermore, neither NK cell activation nor the interferon response were sustained in 
patients undergoing multiple rounds of virus treatment. These results show that 
reovirus modulates human NK cell activity in vivo and suggest that this may 
contribute to any therapeutic effect of this oncolytic virus. Detection of a single, 
transient peak of activation, despite multiple treatment rounds, has implications for 
the design of reovirus-based therapy. Furthermore, our results suggest the existence of 
a post-infection refractory period when the interferon response and NK cell activation 
are blunted. This refractory period has previously been observed in animal models 
and may underlie the enhanced susceptibility to secondary infections that is seen 
following viral infection.  
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Introduction 
Infection induces the rapid activation of innate immunity.  Innate immune activation 
serves two purposes, it limits pathogen replication whilst the clonal selection of B and 
T cells occurs and it favours the development of the appropriate adaptive response [1]. 
Current information on the kinetics of innate immune activation stems largely from 
animal models, yet there is a need to define these processes in humans; such 
knowledge promises to enhance the efficacy of vaccines and other immunotherapeutic 
strategies.  However, studying the early stages of infection in humans presents both 
logistical and ethical problems.   
Natural killer (NK) cells are important in the innate immune response to 
infected cells and to tumours [2, 3]. Early animal studies revealed that NK cell 
activation occurred within two to three days of viral infection [4, 5] and NK cells are 
known to be critical in antiviral immunity [3, 6-9]. Activated NK cells destroy 
infected cells directly and produce cytokines, such as IFN-γ, that favour the 
development of a cytotoxic T cell response [2, 10]. Rare human NK cell deficiencies 
are associated with increased susceptibility to viral infection, revealing the importance 
of human NK cells in antiviral immunity [11, 12]. However, analysing the timeline of 
human NK cell activation in response to viral infection in vivo remains difficult.  
Virus-infected patients show evidence of NK cell activation compared to uninfected 
controls but whilst vaccination allows controlled studies to be performed, the analysis 
of pre-infection status and very early post-infection events remains challenging [3, 
13-18]. Hence, our view of the early stages of NK cell activation is largely based on 
studies performed using model species. 
Reovirus, a non-enveloped dsRNA virus, is pathogenic in mice and induces a 
type I interferon (IFN-I) response [19]. Whilst it is not a significant human pathogen, 
reovirus has the interesting property of preferentially killing tumour cells leading to 
its evaluation as a therapeutic agent [20]. The anti-cancer effects of reovirus and other 
oncolytic viruses appear to be linked to a two-fold mode of action, namely the direct 
killing of tumour cells and the induction of innate and adaptive anti-tumour immunity 
[21-24]. Intravenous delivery of reovirus into patients is associated with its rapid loss 
from the circulation; in eight out of ten treated patients, the virus was undetectable in 
the bloodstream after one hour post-infection [25]. Despite the presence of 
neutralising antibodies, reovirus reached the tumour and was associated with tumour 
cell apoptosis [25]. This same trial allowed us to study infection-induced human NK 
cell activation under controlled conditions.  Our results define the kinetics of human 
NK cell activation in response to viral infection in vivo. 
 
Materials and methods 
Ethical approval and the clinical trial 
This study was undertaken following institutional and national ethical and regulatory 
approval.  Patients were enrolled in the trial and provided blood samples following 
informed consent.  The patient group and the trial are described elsewhere [25].   
 
Antibodies 
The following antibodies were used in this study; CD69 (clone FN50); CD56 (clone 
B159), CD16 (clone 3G8), CD3 (clone SK7), CD107a (clone H4A3), NKG2D (clone 
1D11), DNAM-1 (clone DX11), NKp44 (Clone p44-8.1), NKp46 (clone 9E2), 
CD158a (HP-3E4), CD158b (CH-L), all from BD Biosciences; CD158e (clone DX9) 
from Miltenyi Biotec and Tetherin/CD317 (clone 26F8) from eBiosciences.  For the 
IFN-I blocking experiments, we used a cocktail of anti-IFNα (clone MMHA-2), anti-
IFNβ (clone 76703.111) and rabbit anti-IFNα antiserum, all from PBL Assay Science. 
 
Flow cytometry and gene expression analysis 
Cell surface expression of CD69 and tetherin was determined using flow cytometry 
on either purified NK cells (P1-P4) or by gating on CD56+CD3
neg
 NK cells in 
Peripheral Blood Mononuclear Cells (PBMC; P5-P10). NK cells were purified by 
indirect magnetic immunoselection (Miltenyi Biotech).  Flow cytometry was 
performed using a Becton Dickinson (BD) LSRII or BD FACSCalibur flow cytometer 
using BD FACSDiva software and BD CellQuest Pro software, respectively. For gene 
expression studies, mRNA was converted to cDNA (using random hexamer priming) 
and expression of IFIT1, IFI44L, 18S RNA or ABL1 was analysed by quantitative 
(q)RT-PCR using Taqman reagents from Applied Biosystems.  Data was normalised 
to either 18S RNA or ABL1 mRNA (as indicated) and the fold-change induced during 
infection calculated using the ∆∆Ct method. 
 
 
In vitro studies 
PBMCs from healthy donors were co-incubated with reovirus (REOLYSIN®; 
Oncolytics Biotech Inc.) at a multiplicity of infection (MOI) of 0.2-1 in the presence 
of either the anti-human IFN-I antibody cocktail or matched serum/IgG controls. 
Degranulation assays were performed forty-eight hours post-infection using the K562 
target cell line in the presence of GolgiStop (from BD Biosciences) and the anti-
CD107a antibody [26]. For analysis of isolated NK cells and fractionation of PBMC, 
the NK cells were purified using indirect magnetic immunoselection reagents 
(Miltenyi Biotec) and the NK cell depleted PBMC (PBMC∆NK) were eluted from the 
column. 
 
Results  
Ten patients (P1-10; aged 50-74) with colorectal cancer liver metastases were 
enrolled in a clinical endpoint trial to assess the delivery of reovirus to the metastatic 
tumour [25]. Each patient received between one and five intravenous infusions of 10
10
 
units of reovirus prior to planned surgical resection of their tumour.  Seven of the ten 
patients received reovirus daily for five days, P7 received four doses, P8 a single dose 
and P1 received three doses with an altered timing (Fig. 1a).  Six of the ten patients 
experienced fever and several experienced flu-like symptoms during treatment, 
consistent with viral infection [25].  
Blood samples taken before and during treatment were used to analyse the NK 
cell phenotype. Infection induced rapid expression of the lymphocyte activation 
marker CD69 on the NK cells, peaking forty-eight hours post-infection (Fig. 1b, c).  
A single dose of reovirus was sufficient to induce this activation, as shown in P8 who 
received just one dose and in P1, in whom more than 60% of peripheral blood NK 
cells were CD69+ before the second dose was administered (Fig. 1b). With the 
exception of P1 and P8, all patients received two doses of virus before the forty-eight 
hour sample (when NK cell activation peaked) and a further two doses between the 
forty-eight hour and ninety-six hour samples (Fig. 1a).  However, NK cell activation 
declined after forty-eight hours in all patients, suggesting that NK cells were 
refractory to further stimulation within this period.   
Reovirus dsRNA, and indeed other viral nucleic acids, induce type I interferon 
(IFN-I) responses in animals via pathogen-associated molecular pattern receptor 
recognition. The cytoplasmic RNA sensor RIG-I recognises the 5’-diphosphate 
present on reovirus dsRNA and induces IFN gene expression [27]. It is long 
established that IFN treatment activates human NK cells in vivo [19, 28-30]. CD69 is 
induced via IFN-I responses and we have previously shown that reovirus treatment of 
peripheral blood mononuclear cells (PBMC) in vitro induces CD69 expression by NK 
cells in an IFN-I dependent manner [23]. Expression of the interferon-stimulated 
genes (ISGs) IFIT1 and IFI44L in the reovirus-treated patients showed similar 
kinetics to the induction of NK cell CD69 expression, peaking forty-eight hours post-
infection (Fig. 2a). Like CD69, expression of the ISGs was transient and declined 
after this initial post-infection peak. Collectively, these results are consistent with the 
virus-mediated induction of an IFN-I response in vivo and the IFN-I dependent 
activation of human NK cells within twenty-four to forty-eight hours post-infection.  
Tetherin is an IFN-I inducible antiviral restriction factor and its expression at 
the cell surface provides a convenient marker for IFN-I responses during viral 
infection [31-33]. Tetherin was constitutively expressed at the NK cell surface and 
expression was significantly enhanced following reovirus treatment in vivo, exhibiting 
similar induction kinetics to CD69 and the ISGs (Fig. 2b, c). Human NK cells express 
several activating receptors that have been implicated in the detection of virus-
infected cells, including NKG2D (CD314), DNAM-1 (CD226), NKp30 (CD337) and 
NKp44 (CD336) [3, 34]. Expression of these molecules was not significantly altered 
on patient NK cells at the peak of the IFN-I response and did not show further 
alterations in expression during the course of treatment (Fig. 2b, c).  
We then performed experiments to analyse the response to reovirus in vitro.   
We treated PBMC with reovirus in the presence or absence of antibodies that block 
the IFN-I response. Treated PBMC were then co-cultured with tumour target cells and 
the tumour-mediated degranulation of the NK cells in the PBMC analysed using flow 
cytometry [26]. This demonstrated that reovirus treatment of PBMC resulted in the 
IFN-I dependent, functional activation of the NK cells (Fig. 3a), consistent with 
previously published data [23]. We then treated PBMC with reovirus for forty-eight 
hours, purified the NK cells (using immunomagnetic selection) and analysed the 
expression of IFIT1 mRNA in the NK cell population and in the PBMC depleted of 
NK cells (PBMC∆NK).  Both the NK cells and the PBMC∆NK fraction demonstrated 
substantial induction of IFIT1 mRNA (Fig. 3b). Furthermore, flow cytometry of the 
reovirus-treated PBMC showed the induction of CD69 and tetherin expression on the 
NK cell surface (Fig. 3c), as we observed in the reovirus treated patients (Fig. 1 and 
2). Similar to the situation observed in vivo, the in vitro reovirus treatment did not 
result in substantial changes in the cell surface expression of NKG2D, DNAM-1, 
NKp30, NKp44 or NKp46 on NK cells (Fig. 3c). We did observe a significant 
increase in NKp46 expression in vitro but this only represented a ~1.4 fold increase 
compared to a ~5 fold increase in tetherin expression (Fig. 3c). Cytokines such as IL-
2 and IL-15 increase the cell surface expression of NKG2D and DNAM-1 in vitro 
[26] and a comparison of IL-15 and IFN-I stimulation of purified NK cells showed 
that IL-15 induced expression of NKG2D, DNAM-1, CD69 and tetherin, whereas 
IFN-I only induced CD69 and tetherin, similar to the effects of reovirus treatment we 
observed in vitro and in vivo (Fig. 3d). In conclusion, reovirus treatment, both in vivo 
and in vitro, was associated with the induction of CD69 and tetherin expression at the 
NK cell surface, but with little change in the expression of other NK cell activation 
receptors analysed. The induction of CD69 and tetherin in vivo coincided with the 
peak of IFN-I induced gene expression and both CD69 and tetherin were IFN-I 
inducible in NK cells in vitro. 
These results, showing that reovirus treatment modulates NK cell activation in 
the early post-infection period, are consistent with a role for NK cells in controlling 
viral infection whilst adaptive immunity is developing. Recently, NK cells have been 
shown to have a more durable role in the immune response. The identification of so-
called memory NK cells and the ability of activated NK cells to limit T cell responses 
have revealed that NK cell activity persists beyond this initial wave of activation [14, 
35-37]. Interestingly, we found a significant increase in the absolute numbers of NK 
cells in the pre-surgery samples; in two patients (P9 and P7) we detected a six-fold 
and a thirteen-fold increase respectively (Fig. 4). Expression of KIR molecules is 
clonal and maintained following cell division and KIRs thus provide markers for 
analysis of putative clonal expansions. Cell surface expression of CD158a, CD158b 
and CD158e antigens identified eight distinct populations constituting between ~2% 
through to ~50% of total NK cells (Supplementary Table 1). However, we did not 
detect clonal expansions that could account for the changes in absolute numbers seen 
between the ninety-six hour and pre-surgery samples; this suggests that the increase in 
the absolute numbers of NK cells was due to polyclonal expansion. 
 
 
 
Discussion 
The use of a therapeutic virus within the context of a clinical trial has allowed us to 
analyse the kinetics of human NK cell activation in response to viral infection under 
controlled conditions. Our results demonstrate that human viral infection results in the 
rapid and transient activation of NK cells in the bloodstream and that this activation, 
which occurred within twenty-four to forty-eight hours post-infection, was associated 
with an IFN-I response. Blood samples from healthy volunteers given a poly IC-like 
molecule (a mimic of dsRNA) exhibited similar kinetics of ISG induction and other 
gene expression responses that were consistent with the activation of innate immune 
responses, including those involving NK cells [38]. This work, together with the 
results presented here, are consistent with early studies using mouse models in which 
viral infection resulted in IFN production and the induction of NK cell activation 
within two to three days of infection [4, 5, 39]. In the absence of an IFN-I response, 
viral pathology is enhanced and this is associated with a reduction in infection-
induced NK cell activity [39-41]. However, the effect of IFN-I on NK cells is largely 
indirect, with IFN-I inducing IL-15 production and expression of the IL-15 receptor 
on NK cells; IL-15 then acts upon NK cells [41, 42]. Indeed, several viruses 
(including reovirus) induce IL-15 mRNA in PBMC and activate NK cells in an IL-15 
dependent manner [43]. The early in vivo activation of NK cells in response to 
reovirus treatment is highly suggestive of IFN-I and IL-15 mediated events. However, 
the contribution of other NK cell activating cytokines, such as IL-12 and IL-18 or 
indeed IL-2 (produced predominantly by activated T cells during adaptive immunity) 
cannot be discounted.  
Expression of both CD69 and tetherin is IFN-I inducible. Tetherin was 
originally identified as an IFN-I inducible antiviral restriction molecule with the 
ability to prevent release of HIV [31]. This activity extends to a number of enveloped 
viruses and IFN-I induction of tetherin allows it to act as a broad defense against viral 
spread. Tetherin provides a convenient cell surface marker of an IFN-I induced 
antiviral response [32, 33]. However, our in vitro data show that both tetherin and 
CD69 are inducible in NK cells by IFN-I and IL-15. Others have shown that several 
cytokines can induce tetherin and that its induction can precede IFN-I responses [44-
46]; it remains possible that other cytokines or signals induce CD69 and tetherin in 
response to reovirus infection.  The actual role of CD69 in NK cell activity is poorly 
defined. Activated mouse NK cells traffic from the periphery to the lymph nodes 
where NK cell derived IFN-γ helps to promote cytotoxic T cell responses [10]. In 
mouse B and T lymphocytes, IFN-I induction of CD69 decreases the activity of the 
sphingosine-1-phosphate receptor 1 (S1P1) thereby inhibiting egress from mouse 
secondary lymphoid tissue (SLT) [47]. It is possible that human NK cell expression of 
CD69 causes similar effects, allowing NK cells that traffic from the blood to other 
tissues (such as the SLT) to remain there. However, whilst CD69 inhibits S1P1 
responses in B and T lymphocytes, mouse and human NK cells preferentially express 
S1P5, and this receptor is not inhibited by CD69 [25, 48, 49]. Thus, the role of NK 
cell CD69 remains unclear. Reovirus-activated NK cells may traffic to the liver (the 
site of the colorectal metastases in these patients) where they would be able to attack 
the tumour directly. Whether reovirus-activated NK cells participate directly in 
tumour lysis or whether these activated NK cells mediate other pathways of anti-
tumour immunity via cytokine secretion for example remains unknown. A limitation 
of our study is the inability to analyse NK activation and trafficking beyond the 
peripheral blood. However, the trial did establish that reovirus reaches the tumour 
[25], suggesting that liver-resident NK cells might be activated. Indeed, we have 
previously shown that reovirus can activate liver-derived NK cells in vitro and 
enhance their response to colorectal tumour cell lines [23]. 
Nine of the ten patients in the trial received multiple doses of reovirus, yet 
CD69, tetherin, IFI44L and IFIT1 all exhibited just a single peak of expression 
approximately forty-eight hours after the first dose. For example, all patients except 
P1 and P8 received two further doses of virus between the forty-eight hour and the 
ninety-six hour time points, yet we did not observe a second peak of activation (or 
IFN-I response) and in all cases, responses declined in all patients after forty-eight 
hours post-infection. Furthermore, P1 and P8 revealed that a single dose of virus gave 
a similar magnitude of response to those patients receiving multiple doses; P1 also 
showed that a strong response could be detected within twenty-four hours of 
treatment. The results suggest that the initial IFN-I response (and NK cell activation) 
was followed by a refractory period during which the patients were unable to respond 
to further exposure to reovirus. Most adults have been exposed to reovirus and all 
patients in the trial had neutralising antibodies that increased in titre around days 3-5 
post-infection [25]. Whether this boost in antibody titre blocks the IFN-I response to 
subsequent doses of reovirus seems unlikely, but nevertheless remains unclear. An 
intriguing alternative is that the refractory period is related to that observed in mouse 
viral infection models [50, 51]; the initial viral infection induces an IFN response 
which is followed by a refractory period in which further IFN responses to unrelated 
pathogens are blunted. This refractory period has been suggested to contribute to the 
enhanced susceptibility to unrelated, secondary infections that can follow viral 
infection. In mice, the mechanisms underlying this refractory period include a reduced 
capacity of plasmacytoid dendritic cells (pDC) to produce IFN [51] and the induction 
of OASL1, a negative regulator of IFN production [52]. However, other homeostatic 
control mechanisms that halt responses, including molecules that target IFN 
production and downstream signalling pathways, may also influence responses [53-
57]. Interestingly, tetherin was proposed to act as a feedback inhibitor of IFN 
production by engaging the receptor ILT7 on pDC [58]. However, whilst ILT7 
ligation was confirmed to halt IFN production, a role for tetherin in this process was 
subsequently called into question [59]. To the best of our knowledge, the data 
presented here is the first demonstration of this refractory period in humans. However, 
the constraints of working within a clinical trial make these conclusions speculative. 
Furthermore, applying these findings to the general population also warrants caution 
because all of the patients in the trial have metastatic cancer, presumably associated 
with alterations in immune status. Notwithstanding the limitations of our study, the 
clinical importance of opportunistic infections following acute viral infection (e.g. 
with influenza), or chronic infections (such as HIV) cannot be understated. From a 
cancer therapy perspective, our results indicate that the scheduling of oncolytic 
viruses will require optimisation, if IFN-I and NK cell responses are to be maximised. 
Whilst profound effects were observed in the first forty-eight hours post-
infection, we also observed a later change in NK cells, namely a significant increase 
in the absolute numbers of NK cells.  In HIV infection there is an expansion of 
particular KIR expressing cells [16]. We did not detect particular clonal expansions 
using antibodies that detect CD158 family molecules that include KIR2DL1, 
KIR2DL3 and KIR3DL1 (as well as related short form KIRs). This panel identified 
approximately 30-50% of total NK cells, consistent with more detailed KIR 
phenotyping where approximately 50% of NK cells lack KIR expression [60]. 
However, we did not analyse expression of NKG2C expressing cells; this population 
expands in both cytomegalovirus and hantavirus infection and for the latter, expanded 
cells expressed at least one KIR molecule against a self-MHC class I molecule, 
indicating that the expanded NK cells were functionally licensed [14, 61]. The KIR 
and MHC haplotype of the patients within our study was unavailable to us and we do 
not know whether the expansions we detected were confined to licensed populations. 
The significance of this relatively late post-infection phenotype is unclear. There is 
emerging data that suggest a role for NK cells beyond the immediate post-infection 
stage [14].  The significance of these more durable NK cell responses, for example 
whether they represent the formation of a memory-like NK cell population [35], or a 
role for NK cells in the cessation of T cell responses currently remains unclear [36, 
37].  
The ability of reovirus to induce NK cell activation is likely to contribute to its 
oncolytic activity in vivo. However, effective oncolytic virus treatment will depend 
upon achieving the correct balance of antiviral and anti-tumour activity [20, 62]. For 
example, depletion of NK cells limits the efficacy of both vesicular stomatitis virus 
and reovirus virus treatment, consistent with stimulation of the anti-tumour effector 
function of this population [63, 64]. However, the antiviral activity of NK cells has 
been shown to impede the action of oncolytic herpes simplex virus against 
glioblastoma [65].  In the patients treated here, replication competent reovirus was 
recovered from the colorectal liver metastases but not from surrounding healthy tissue, 
suggesting effective targeting of the virus to the tumour [25]. Furthermore, ex vivo 
studies show that reovirus activates NK cells from the liver and enhances their 
cytotoxic activity towards colorectal cancer cell lines [23]. However, viral infection in 
the liver can induce potent immunosuppressive activity (via IL-10 and TGF-β) that 
limits NK cell production of IFN-γ; similar effects would be expected to blunt 
oncolytic virus induced NK cell activation and anti-tumour immunity [66]. 
In summary, use of a therapeutic virus in a clinical trial has enabled us to 
study the kinetics of NK cell activation in response to viral infection. The increasing 
use of therapeutic viruses promises to provide new opportunities to study the 
activation and resolution of the human immune response in vivo and provide key 
information that is currently inferred from studies performed in other species. 
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Figure legends 
 
Figure 1. Human NK cell activation by reovirus in vivo.   
(a) Schedule of patient infection and sampling during the reovirus clinical trial. Four 
different schedules were employed. Patients (P)2, 3, 4, 5, 6, 9 and 10 were treated 
according to the schedule shown at the top. The variations for P7, P8 and P1 are 
shown below. The time of infection is shown above the horizontal line (grey vertical 
arrow) and the time of blood sampling below (black vertical arrow). Times of blood 
sampling (time post-infection) are shown in hours (0, 1, 24, 48, 72, 96), immediately 
prior to surgery (Sgy) and in months (1Mo, 3Mo). The indicated variations were made 
according to clinical parameters, which together with patient details and timing of the 
surgery, have previously been reported [25]. Each infusion consisted of 10
10
 units of 
reovirus, with one unit defined as the dose of virus required to kill 50% of cultured 
cells in vitro (the Tissue Culture Infective Dose 50% or TCID50). 
(b) NK cell surface expression of CD69 in selected patients representing key 
variations to the schedule, and in a healthy control (HC); P3 represents the patients 
with repeated doses, P8 had a single dose and P1 underwent treatment with altered 
timing to the other patients. The time post-infection is shown with 0 hour immediately 
prior to the first infusion. The values in grey indicate the percentage of CD69 
expressing NK cells compared to isotype control stains that were performed for all 
analyses (not shown).  
(c) Summary of CD69 expression in patients P2-10 and in healthy control (HC) 
donors (n=7).  The P values were calculated using the Mann-Whitney test; 
P<0.001***. P1 data is omitted from this analysis because of the altered timing of 
therapy. 
 
Figure 2.  Interferon responses and changes in the NK cell surface phenotype in vivo.  
(a) Expression of the interferon stimulated genes (ISGs) IFIT1 and IFI44L following 
reovirus treatment, as determined by quantitative RT-PCR. The analyses were 
performed using NK cells purified from P5 or from whole PBMC isolated from P7. 
The data shows expression in the treated patient (black lines and squares) and in an 
uninfected control (grey lines and diamonds).  Expression was calculated as the fold-
change in expression compared to the pre-infection (0 hour) timepoint (assigned a 
value of 1 unit of expression).   
(b) Expression of NK cell receptors in patients at pre-infection (0hr) timepoint (-) and 
48 hours post-infection (+). Data shows the change in mean fluorescence intensity 
(MFI) with the expression at the 0 hour timepoint assigned a value of 1. The number 
of patients in each group is indicated (n). Data (where n>2) was analysed using the 
Student’s T test and statistically significant differences are shown; P<0.05*.  
(c) Flow cytometric analysis of expression of patient NK cell surface molecules 
throughout the treatment course. The grey dotted line shows the approximate position 
of the median fluorescence intensity of the signal at the pre-infection timepoint. The 
plots are from individual patients (shown) and are representative of data collected 
across the treatment group; only tetherin (and CD69, Fig.1) showing substantial 
alterations in expression. Tetherin expression was not determined at the three-month 
(3Mo) timepoint. 
 
Figure 3. Analysis of NK cell responses to reovirus treatment in vitro. 
(a) Reovirus and IFN-I mediated activation of NK cell granule exocytosis. The left 
hand panel shows the display of cell surface CD107 (gated on CD56+CD3
neg
 NK 
cells within PBMC) in the presence or absence of K562 target cells. The experiment 
was performed using PBMC from healthy donors without further treatment 
(untreated), in the presence of 0.2 MOI reovirus (+virus) and in the presence of 
reovirus and an anti-IFN antibody or a control antibody (cAb). The percentage values 
indicate the proportion of CD107+ NK cells for each treatment. Statistical analysis 
was performed between the indicated pairs of treatments using the Student’s T test; 
P<0.05*. Limitations in the size of samples available from the clinical trial made 
cytotoxicity assays from the in vivo study difficult to perform. However, of three 
patients analysed, one showed increased cytotoxic activity 48 hours post-infection 
(data not shown). 
(b) Expression of IFIT1 mRNA in NK cells and NK cell-depleted PBMC 
(PBMC∆NK) with (+) and without (-) reovirus treatment in vitro. Whole PBMC 
(from healthy donors) were treated with reovirus (at an MOI of 1), cultured for 48 
hours and fractionated into NK cells and NK-depleted PBMC (using magnetic 
indirect selection of NK cells). RT-PCR for IFIT1 and ABL1 was performed using 
mRNA isolated from these fractions; IFIT1 expression was normalised to ABL1 
mRNA and the fold-change induced during infection calculated via the ∆∆Ct, with 
the untreated cells (-) assigned an expression value of 1 unit. The data shown is from 
two different donors.  
(c) The expression of NK cell surface markers +/- reovirus treatment in vitro, 
analysed 48 hours post-infection. The right hand panel indicates the percentage of 
CD69 expressing NK cells in the PBMC population, the left hand panel indicates the 
change in mean fluorescence intensity of the indicated markers. Statistical analysis 
was performed using the Student’s T test; P<0.05*, P<0.01**, P<0.001***. 
(d) Expression of NK cell surface molecules following cytokine treatment in vitro. 
Purified NK cells (from healthy donors) were treated with 20ng/ml of IL-15 or 100 IU 
IFN-I for 48 hours and expression of the indicated markers was analysed by flow 
cytometry. The dotted grey line shows the approximate position of the mean 
fluorescence intensity of the isotype control for CD69 or for expression of the other 
markers in untreated cells.   
 
Figure 4. Absolute numbers of NK cells (cells per µl) in patients during the treatment 
course. The values at each timepoint were compared to the pre-treatment 0 hour 
timepoint using the Mann-Whitney test, only the statistically significant differences 
are shown; P<0.05*. The normal range for the absolute number of NK cells in healthy 
donors is ~90-600 cells per µl. 
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P7 ~13x P8 ~2x P9 ~6x P10 ~2x 
CD158 96hr Sgy 96hr Sgy 96hr Sgy 96hr Sgy 
ABE 2.12 2.35 1.19 0.95 0.1 0.06 1.95 2.19 
ABe 6.21 
 
6.15 
 
8.65 5.89 9.00 9.35 6.19 5.63 
AbE 7.37 9.39 3.81 2.95 0.00 0.02 4.16 3.87 
aBE 2.71 3.24 1.94 0.85 0.03 0.02 2.65 2.49 
Abe 6.97 6.17 11.38 7.78 5.99 6.36 9.43 8.69 
aBe 11.9 12.48 17.41 12.77 26.53 28.14 14.69 16.02 
abE 4.78 5.65 2.38 1.39 0.07 
 
0.04 
 
3.83 2.57 
abe 57.94 54.56 53.24 67.42 58.29 56.01 57.10 58.54 
Supplementary Table 1: Clonal analysis of NK cell populations. 
 
NK cells from P7-10 were analysed for expression of CD158a, b and e at ninety-six hours post-infection and in the pre-surgery sample (Sgy). 
The fold change in absolute numbers of NK cells between these two samples is shown next to the patient number (e.g. for P7, ~13X). The 
values indicate the size of the respective populations as a percentage of the total CD56+CD3neg NK cells. 
The three markers identify eight distinct populations listed in the left hand column. Expressed CD158 molecules are denoted by upper case 
letters (e.g. ABC is CD158a+, b+, c+) or lower case for non-expressed (abc denotes the triple negative population of CD158aneg, bneg, cneg).   
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